Paradoxical effects of the cannabinoid CB2 receptor agonist GW405833 on rat osteoarthritic knee joint pain

Osteoarthritis and Cartilage

Volumn 18, Issue 11, 2010, Pages 1536-1543

  Schuelert, N ^a   Zhang, C ^a   Mogg, A J ^b   Broad, L M ^b   Hepburn, D L ^b   Nisenbaum, E S ^b   Johnson, M P ^b   McDougall, J J ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Animal model; Cannabinoid CB2 receptor; Electrophysiological recordings; Joint pain; Osteoarthritis; Primary joint afferents; Transient receptor potential vanilloid channel 1

Indexed keywords

1 (2,3 DICHLOROBENZOYL) 5 METHOXY 2 METHYL 3 (2 MORPHOLINOETHYL)INDOLE; 4 CHLORO N (3 METHOXYPHENYL)CINNAMAMIDE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; CALCITONIN GENE RELATED PEPTIDE; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; NEUROPEPTIDE; VANILLOID RECEPTOR 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRALGIA; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; IMMUNOHISTOCHEMISTRY; INFLAMMATION; KNEE OSTEOARTHRITIS; MALE; MECHANORECEPTOR; NERVE CELL; NERVE FIBER; NOCICEPTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT; SENSORY NERVE; SPINAL GANGLION; SYNOVIOCYTE; SYNOVIUM;

ANIMALS; CANNABINOIDS; DISEASE MODELS, ANIMAL; ELECTROPHYSIOLOGY; GANGLIA, SPINAL; IMMUNOHISTOCHEMISTRY; INDOLES; INJECTIONS, INTRA-ARTICULAR; KNEE JOINT; MALE; MORPHOLINES; NERVE FIBERS; OSTEOARTHRITIS, KNEE; PAIN; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB2; SYNOVIAL MEMBRANE; TRPV CATION CHANNELS;

EID: 78149412739     PISSN: 10634584     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joca.2010.09.005     Document Type: Article

References (49)

1. Bove S.E., Calcaterra S.L., Brooker R.M., Huber C.M., Guzman R.E., Juneau P.L., et al. Weight bearing as a measure of disease progression and efficacy of anti-inflammatory compounds in a model of monosodium iodoacetate-induced osteoarthritis. Osteoarthritis Cartilage 2003, 11:821-830.
2. Combe R., Bramwell S., Field M.J. The monosodium iodoacetate model of osteoarthritis: a model of chronic nociceptive pain in rats?. Neurosci Lett 2004, 370:236-240.
3. Fernihough J., Gentry C., Malcangio M., Fox A., Rediske J., Pellas T., et al. Pain related behaviour in two models of osteoarthritis in the rat knee. Pain 2004, 112:83-93.
4. Guingamp C., Gegout-Pottie P., Philippe L., Terlain B., Netter P., Gillet P. Mono-iodoacetate-induced experimental osteoarthritis: a dose-response study of loss of mobility, morphology, and biochemistry. Arthritis & Rheum 1997, 40:1670-1679.
5. Kalbhen D.A. Chemical model of osteoarthritis-a pharmacological evaluation. J Rheum 1987, 14:130-131.
6. McDougall J.J., Watkins L., Li Z. Vasoactive intestinal peptide (VIP) is a modulator of joint pain in a rat model of osteoarthritis. Pain 2006, 123:98-105.
7. Schuelert N., McDougall J.J. Cannabinoid-mediated antinociception is enhanced in rat osteoarthritic knees. Arthritis Rheum 2008, 58:145-153.
8. Cox M.L., Haller V.L., Welch S.P. The antinociceptive effect of Delta9-tetrahydrocannabinol in the arthritic rat involves the CB(2) cannabinoid receptor. Eur J Pharmacol 2007, 570:50-56.
9. Smith F.L., Fujimori K., Lowe J., Welch S.P. Characterization of delta9-tetrahydrocannabinol and anandamide antinociception in nonarthritic and arthritic rats. Pharmacol Biochem Behav 1998, 60:183-191.
10. Cox M.L., Welch S.P. The antinociceptive effect of delta9-tetrahydrocannabinol in the arthritic rat. Eur J Pharmacol 2004, 493:65-74.
11. Galiegue S., Mary S., Marchand J., Dussossoy D., Carriere D., Carayon P., et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 1995, 232:54-61.
12. Herkenham M., Lynn A.B., Little M.D., Johnson M.R., Melvin L.S., de Costa B.R., et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A 1990, 87:1932-1936.
13. Ibrahim M.M., Deng H., Zvonok A., Cockayne D.A., Kwan J., Mata H.P., et al. Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci U S A 2003, 100:10529-10533.
14. Malan T.P., Ibrahim M.M., Deng H., Liu Q., Mata H.P., Vanderah T., et al. CB2 cannabinoid receptor-mediated peripheral antinociception. Pain 2001, 93:239-245.
15. Nackley A.G., Makriyannis A., Hohmann A.G. Selective activation of cannabinoid CB(2) receptors suppresses spinal fos protein expression and pain behavior in a rat model of inflammation. Neuroscience 2003, 119:747-757.
16. Sanson M., Bueno L., Fioramonti J. Involvement of cannabinoid receptors in inflammatory hypersensitivity to colonic distension in rats. Neurogastroenterol Motil 2006, 18:949-956.
17. Quartilho A., Mata H.P., Ibrahim M.M., Vanderah T.W., Porreca F., Makriyannis A., et al. Inhibition of inflammatory hyperalgesia by activation of peripheral CB2 cannabinoid receptors. Anesthesiology 2003, 99:955-960.
18. Yao B.B., Hsieh G.C., Frost J.M., Fan Y., Garrison T.R., Daza A.V., et al. In vitro and in vivo characterization of A-796260: a selective cannabinoid CB2 receptor agonist exhibiting analgesic activity in rodent pain models. Br J Pharmacol 2008, 153:390-401.
19. Hanus L., Breuer A., Tchilibon S., Shiloah S., Goldenberg D., Horowitz M., et al. HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. Proc Natl Acad Sci U S A 1999, 96:14228-14233.
20. Clayton N., Marshall F.H., Bountra C., O'Shaughnessy C.T. CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain. Pain 2002, 96:253-260.
21. Whiteside G.T., Gottshall S.L., Boulet J.M., Chaffer S.M., Harrison J.E., Pearson M.S., et al. A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833. Eur J Pharmacol 2005, 528:65-72.
22. Zygmunt P.M., Petersson J., Andersson D.A., Chuang H., Sorgard M., Di Marzo V., et al. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 1999, 400:452-457.
23. Smart D., Jerman J.C. Anandamide: an endogenous activator of the vanilloid receptor. Trends Pharmacol Sci 2000, 21:134.
24. Baker C.L., McDougall J.J. The cannabinomimetic arachidonyl-2-chloroethylamide (ACEA) acts on capsaicin-sensitive TRPV1 receptors but not cannabinoid receptors in rat joints. Br J Pharmacol 2004, 142:1361-1367.
25. Anand U., Otto W.R., Sanchez-Herrera D., Facer P., Yiangou Y., Korchev Y., et al. Cannabinoid receptor CB2 localisation and agonist-mediated inhibition of capsaicin responses in human sensory neurons. Pain 2008, 138:667-680.
26. Caterina M.J., Schumacher M.A., Tominaga M., Rosen T.A., Levine J.D., Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997, 389:816-824.
27. Costa B., Giagnoni G., Franke C., Trovato A.E., Colleoni M. Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation. Br J Pharmacol 2004, 143:247-250.
28. Davis J.B., Gray J., Gunthorpe M.J., Hatcher J.P., Davey P.T., Overend P., et al. Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia. Nature 2000, 405:183-187.
29. Smart D., Gunthorpe M.J., Jerman J.C., Nasir S., Gray J., Muir A.I., et al. The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Br J Pharmacol 2000, 129:227-230.
30. Neugebauer V., Rumenapp P., Schaible H.G. Calcitonin gene-related peptide is involved in the spinal processing of mechanosensory input from the rat's knee joint and in the generation and maintenance of hyperexcitability of dorsal horn-neurons during development of acute inflammation. Neuroscience 1996, 71:1095-1109.
31. Zhang L., Hoff A.O., Wimalawansa S.J., Cote G.J., Gagel R.F., Westlund K.N. Arthritic calcitonin/alpha calcitonin gene-related peptide knockout mice have reduced nociceptive hypersensitivity. Pain 2001, 89:265-273.
32. Mogg A.J., Mill C.B.R., Wiernicki T.R., Blanco M., Beck J.P., Lm B. Pharmacological profiling of native TRPV1 from adult rat spinal cord. Soc Neuro Abs 2007, 143(10).
33. Just S., Pawlak M., Heppelmann B. Responses of fine primary afferent nerve fibres innervating the rat knee joint to defined torque. J Neurosci Methods 2000, 103:157-162.
34. McDougall J.J., Pawlak M., Hanesch U., Schmidt R.F. Peripheral modulation of rat knee joint afferent mechanosensitivity by nociceptin/orphanin FQ. Neurosci Lett 2000, 288:123-126.
35. Beltramo M., Bernardini N., Bertorelli R., Campanella M., Nicolussi E., Fredduzzi S., et al. CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms. Eur J Neurosci 2006, 23:1530-1538.
36. Wotherspoon G., Fox A., McIntyre P., Colley S., Bevan S., Winter J. Peripheral nerve injury induces cannabinoid receptor 2 protein expression in rat sensory neurons. Neuroscience 2005, 135:235-245.
37. Zhang J., Hoffert C., Vu H.K., Groblewski T., Ahmad S., O'Donnell D. Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models. Eur J Neurosci 2003, 17:2750-2754.
38. Richardson D., Pearson R.G., Kurian N., Latif M.L., Garle M.J., Barrett D.A., et al. Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis. Arthritis Res Ther 2008, 10:R43.
39. McDougall J.J., Yu V., Thomson J. In vivo effects of CB(2) receptor-selective cannabinoids on the vasculature of normal and arthritic rat knee joints. Br J Pharmacol 2008, 153:358-366.
40. Nackley A.G., Suplita R.L., Hohmann A.G. A peripheral cannabinoid mechanism suppresses spinal fos protein expression and pain behavior in a rat model of inflammation. Neuroscience 2003, 117:659-670.
41. Valenzano K.J., Tafesse L., Lee G., Harrison J.E., Boulet J.M., Gottshall S.L., et al. Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. Neuropharmacology 2005, 48:658-672.
42. Elmes S.J., Winyard L.A., Medhurst S.J., Clayton N.M., Wilson A.W., Kendall D.A., et al. Activation of CB1 and CB2 receptors attenuates the induction and maintenance of inflammatory pain in the rat. Pain 2005, 118:327-335.
43. Jhaveri M.D., Elmes S.J., Richardson D., Barrett D.A., Kendall D.A., Mason R., et al. Evidence for a novel functional role of cannabinoid CB(2) receptors in the thalamus of neuropathic rats. Eur J Neurosci 2008, 27:1722-1730.
44. Harper A.A., Lawson S.N. Conduction velocity is related to morphological cell type in rat dorsal root ganglion neurones. J Physiol 1985, 359:31-46.
45. Bhave G., Zhu W., Wang H., Brasier D.J., Oxford G.S., Gereau R.W. cAMP-dependent protein kinase regulates desensitization of the capsaicin receptor (VR1) by direct phosphorylation. Neuron 2002, 35:721-731.
46. Lizanecz E., Bagi Z., Pasztor E.T., Papp Z., Edes I., Kedei N., et al. Phosphorylation-dependent desensitization by anandamide of vanilloid receptor-1 (TRPV1) function in rat skeletal muscle arterioles and in Chinese hamster ovary cells expressing TRPV1. Mol Pharmacol 2006, 69:1015-1023.
47. De Petrocellis L., Harrison S., Bisogno T., Tognetto M., Brandi I., Smith G.D., et al. The vanilloid receptor (VR1)-mediated effects of anandamide are potently enhanced by the cAMP-dependent protein kinase. J Neurochem 2001, 77:1660-1663.
48. Premkumar L.S., Ahern G.P. Induction of vanilloid receptor channel activity by protein kinase C. Nature 2000, 408:985-990.
49. Carlton S.M., Du J., Zhou S., Coggeshall R.E. Tonic control of peripheral cutaneous nociceptors by somatostatin receptors. J Neurosci 2001, 21:4042-4049.